{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:57:04Z","timestamp":1759334224611,"version":"build-2065373602"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["ARS01_00345"],"award-info":[{"award-number":["ARS01_00345"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Rare diseases are chronic, progressive, and debilitating conditions, affecting 3.5\u20135.9% of the global population. Clinical research studies are crucial for developing new diagnostic approaches and treatments and for overcoming the lack of awareness and the need of expertise surrounding these diseases. Involving patient organizations in clinical studies is widely considered a promising approach, to overcome barriers and to facilitate research activities. The aim of this paper is to present the actions taken, the relevant results, and the lessons learned from involving a patient organization in shaping, conducting, and disseminating a clinical study on rare patients with Osteogenesis Imperfecta.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In a context of a clinical study in which patients underwent a comprehensive, fully instrumental gait analysis and an evaluation of specific movement tasks using stereophotogrammetry and wearable sensors, we assessed all the actions taken and the results achieved by the implementation of an original collaborative model between a public institution and a national patient organization. To generalize our collaborative experience, steps and stages of the research process that can benefit the most from the support of a patient organization were identified, experimental protocol drafting, ethic committee approval, patient enrolment, and dissemination. Patients reported positive feedback in a short questionnaire on the use case experience. Moreover, we highlighted the gains and the weaknesses of this approach.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This experience resulted in several benefits for all the actors involved, strengthening the collaboration between the PO and researchers and fostering a cohesive and cooperative network.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03986-9","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:50:22Z","timestamp":1759236622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Involvement of patient organisations in research activities: actions taken and lessons learned in a clinical research study for osteogenesis imperfecta"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2085-3065","authenticated-orcid":false,"given":"Marina","family":"Mordenti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Panzeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4777-341X","authenticated-orcid":false,"given":"Alice","family":"Moroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-1772","authenticated-orcid":false,"given":"Manila","family":"Boarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4965-5747","authenticated-orcid":false,"given":"Marta","family":"Calzolari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4284-8618","authenticated-orcid":false,"given":"Francesca","family":"Gurioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Pollicini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9301-9461","authenticated-orcid":false,"given":"Giulia","family":"Rogati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3547-7370","authenticated-orcid":false,"given":"Alberto","family":"Leardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3658-1209","authenticated-orcid":false,"given":"Luca","family":"Sangiorgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"3986_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2006.01666.x","author":"M W\u00e4stfelt","year":"2006","unstructured":"W\u00e4stfelt M, Fadeel B, Henter JI. A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med. 2006. https:\/\/doi.org\/10.1111\/j.1365-2796.2006.01666.x.","journal-title":"J Intern Med"},{"key":"3986_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1028545","author":"CCY Chung","year":"2022","unstructured":"Chung CCY, Hong Kong Genome Project, Chu ATW, Chung BHY. Rare disease emerging as a global public health priority. Front Public Health. 2022. https:\/\/doi.org\/10.3389\/fpubh.2022.1028545.","journal-title":"Front Public Health"},{"key":"3986_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.61124","author":"CR Ferreira","year":"2019","unstructured":"Ferreira CR. The burden of rare diseases. Am J Med Genet A. 2019. https:\/\/doi.org\/10.1002\/ajmg.a.61124.","journal-title":"Am J Med Genet A"},{"key":"3986_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-019-0508-0","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020. https:\/\/doi.org\/10.1038\/s41431-019-0508-0.","journal-title":"Eur J Hum Genet"},{"key":"3986_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2021.01.003","author":"HI Roessler","year":"2021","unstructured":"Roessler HI, Knoers NVAM, van Haelst MM, van Haaften G. Drug repurposing for rare diseases. Trends Pharmacol Sci. 2021. https:\/\/doi.org\/10.1016\/j.tips.2021.01.003.","journal-title":"Trends Pharmacol Sci"},{"key":"3986_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/apa.15974","author":"SC Groft","year":"2021","unstructured":"Groft SC, Posada M, Taruscio D. Progress, challenges and global approaches to rare diseases. Acta Paediatr. 2021. https:\/\/doi.org\/10.1111\/apa.15974.","journal-title":"Acta Paediatr"},{"key":"3986_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-67144-4_6","author":"R Gopal-Srivastava","year":"2017","unstructured":"Gopal-Srivastava R, Kaufmann P. Facilitating clinical studies in rare diseases. Adv Exp Med Biol. 2017. https:\/\/doi.org\/10.1007\/978-3-319-67144-4_6.","journal-title":"Adv Exp Med Biol"},{"key":"3986_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02317-6","author":"CQ Nguyen","year":"2022","unstructured":"Nguyen CQ, Alba-Concepcion K, Palmer EE, Scully JL, Millis N, Farrar MA. The involvement of rare disease patient organisations in therapeutic innovation across rare paediatric neurological conditions: a narrative review. Orphanet J Rare Dis. 2022. https:\/\/doi.org\/10.1186\/s13023-022-02317-6.","journal-title":"Orphanet J Rare Dis"},{"key":"3986_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31533","author":"L Abrahamyan","year":"2016","unstructured":"Abrahamyan L, Feldman BM, Tomlinson G, et al. Alternative designs for clinical trials in rare diseases. Am J Med Genet C Semin Med Genet. 2016. https:\/\/doi.org\/10.1002\/ajmg.c.31533.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"3986_CR10","doi-asserted-by":"publisher","first-page":"g6802","DOI":"10.1136\/bmj.g6802","volume":"349","author":"JJ Gagne","year":"2014","unstructured":"Gagne JJ, Thompson L, O\u2019Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ. 2014;349:g6802. https:\/\/doi.org\/10.1136\/bmj.g6802. Published 2014 Nov 24.","journal-title":"BMJ"},{"issue":"1","key":"3986_CR11","first-page":"e66","volume":"21","author":"L Abrahamyan","year":"2014","unstructured":"Abrahamyan L, Diamond IR, Johnson SR, Feldman BM. A new toolkit for conducting clinical trials in rare disorders. J Popul Ther Clin Pharmacol. 2014;21(1):e66\u201378.","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"3986_CR12","unstructured":"EU website. ERNs overview: https:\/\/health.ec.europa.eu\/european-reference-networks\/overview_en. Accessed 31\/07\/2025."},{"key":"3986_CR13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-091212-153525","author":"PP Koay","year":"2013","unstructured":"Koay PP, Sharp RR. The role of patient advocacy organizations in shaping genomic science. Annu Rev Genomics Hum Genet. 2013. https:\/\/doi.org\/10.1146\/annurev-genom-091212-153525.","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"3986_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-014-2895-9","author":"LP Forsythe","year":"2014","unstructured":"Forsythe LP, Szydlowski V, Murad MH, et al. A systematic review of approaches for engaging patients for research on rare diseases. J Gen Intern Med. 2014. https:\/\/doi.org\/10.1007\/s11606-014-2895-9.","journal-title":"J Gen Intern Med"},{"key":"3986_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/26330040231164425","author":"AM Patterson","year":"2023","unstructured":"Patterson AM, O\u2019Boyle M, VanNoy GE, Dies KA. Emerging roles and opportunities for rare disease patient advocacy groups. Ther Adv Rare Dis. 2023. https:\/\/doi.org\/10.1177\/26330040231164425.","journal-title":"Ther Adv Rare Dis"},{"key":"3986_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2022.08.007","author":"M Chopra","year":"2022","unstructured":"Chopra M, Modi ME, Dies KA, et al. GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapy. Mol Ther Methods Clin Dev. 2022. https:\/\/doi.org\/10.1016\/j.omtm.2022.08.007.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3986_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-020-00332-1","author":"V Boulanger","year":"2020","unstructured":"Boulanger V, Schlemmer M, Rossov S, Seebald A, Gavin P. Establishing patient registries for rare diseases: rationale and challenges. Pharmaceut Med. 2020. https:\/\/doi.org\/10.1007\/s40290-020-00332-1.","journal-title":"Pharmaceut Med"},{"key":"3986_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1299232","author":"M Mordenti","year":"2024","unstructured":"Mordenti M, Boarini M, Banchelli F, et al. Osteogenesis imperfecta: a cross-sectional study of skeletal and extraskeletal features in a large cohort of Italian patients. Front Endocrinol (Lausanne). 2024. https:\/\/doi.org\/10.3389\/fendo.2023.1299232.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3986_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/gim.0b013e3182310ba0","author":"DC Landy","year":"2012","unstructured":"Landy DC, Brinich MA, Colten ME, Horn EJ, Terry SF, Sharp RR. How disease advocacy organizations participate in clinical research: a survey of genetic organizations. Genet Med. 2012. https:\/\/doi.org\/10.1038\/gim.0b013e3182310ba0.","journal-title":"Genet Med"},{"key":"3986_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaitpost.2006.12.018","author":"A Leardini","year":"2007","unstructured":"Leardini A, Sawacha Z, Paolini G, Ingrosso S, Nativo R, Benedetti MG. A new anatomically based protocol for gait analysis in children. Gait Posture. 2007. https:\/\/doi.org\/10.1016\/j.gaitpost.2006.12.018.","journal-title":"Gait Posture"},{"key":"3986_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiomech.2011.01.015","author":"A Leardini","year":"2011","unstructured":"Leardini A, Biagi F, Merlo A, Belvedere C, Benedetti MG. Multi-segment trunk kinematics during locomotion and elementary exercises. Clin Biomech (Bristol Avon). 2011. https:\/\/doi.org\/10.1016\/j.clinbiomech.2011.01.015.","journal-title":"Clin Biomech (Bristol Avon)"},{"key":"3986_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1475-925X-13-146","author":"F Bugan\u00e8","year":"2014","unstructured":"Bugan\u00e8 F, Benedetti MG, D\u2019Angeli V, Leardini A. Estimation of pelvis kinematics in level walking based on a single inertial sensor positioned close to the sacrum: validation on healthy subjects with stereophotogrammetric system. Biomed Eng Online. 2014. https:\/\/doi.org\/10.1186\/1475-925X-13-146.","journal-title":"Biomed Eng Online"},{"key":"3986_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-017-0310-5","author":"NJ Devlin","year":"2017","unstructured":"Devlin NJ, Brooks R. EQ-5D and the EuroQol group: past, present and future. Appl Health Econ Health Policy. 2017. https:\/\/doi.org\/10.1007\/s40258-017-0310-5.","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"3986_CR24","doi-asserted-by":"publisher","first-page":"M28","DOI":"10.1093\/gerona\/50a.1.m28","volume":"50A","author":"LE Powell","year":"1995","unstructured":"Powell LE, Myers AM. The Activities-specific balance confidence (ABC) scale. J Gerontol Biol Sci Med Sci. 1995;50A(1):M28\u201334. https:\/\/doi.org\/10.1093\/gerona\/50a.1.m28.","journal-title":"J Gerontol Biol Sci Med Sci"},{"key":"3986_CR25","doi-asserted-by":"publisher","DOI":"10.7748\/ns.29.27.44.e8745","author":"L Gelling","year":"2015","unstructured":"Gelling L. Stages in the research process. Nurs Stand. 2015. https:\/\/doi.org\/10.7748\/ns.29.27.44.e8745.","journal-title":"Nurs Stand"},{"key":"3986_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/hex.12888","author":"T Greenhalgh","year":"2019","unstructured":"Greenhalgh T, Hinton L, Finlay T, et al. Frameworks for supporting patient and public involvement in research: systematic review and co-design pilot. Health Expect. 2019. https:\/\/doi.org\/10.1111\/hex.12888.","journal-title":"Health Expect"},{"key":"3986_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12910-020-0460-0","author":"JT Martineau","year":"2020","unstructured":"Martineau JT, Minyaoui A, Boivin A. Partnering with patients in healthcare research: a scoping review of ethical issues, challenges, and recommendations for practice. BMC Med Ethics. 2020. https:\/\/doi.org\/10.1186\/s12910-020-0460-0.","journal-title":"BMC Med Ethics"},{"key":"3986_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s40900-016-0044-9","author":"A Heaven","year":"2016","unstructured":"Heaven A, Brown L, Foster M, Clegg A. Keeping it credible in cohort multiple randomised controlled trials: the community ageing research 75+ (CARE 75+) study model of patient and public involvement and engagement. Res Involv Engagem. 2016. https:\/\/doi.org\/10.1186\/s40900-016-0044-9.","journal-title":"Res Involv Engagem"},{"issue":"4","key":"3986_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.15252\/embr.201744065","volume":"18","author":"H Wolinsky","year":"2017","unstructured":"Wolinsky H. Charities and the lure of capitalism: philanthropies dedicated to finding cures for rare diseases explore new models for funding and Cooperation to accelerate research and drug development. EMBO Rep. 2017;18(4):519\u201322. https:\/\/doi.org\/10.15252\/embr.201744065.","journal-title":"EMBO Rep"},{"key":"3986_CR30","unstructured":"European Organisation for Rare Diseases. \u2013 EURORDIS: https:\/\/www.eurordis.org\/Accessed31\/07\/\/2025"},{"key":"3986_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.1965","author":"AA Mitani","year":"2020","unstructured":"Mitani AA, Haneuse S. JAMA Netw Open. 2020;3(3):e201965. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.1965. Small Data Challenges of Studying Rare Diseases."},{"key":"3986_CR32","doi-asserted-by":"publisher","first-page":"1098454","DOI":"10.3389\/fneur.2023.1098454","volume":"14","author":"A Videnovic","year":"2023","unstructured":"Videnovic A, Pfeiffer HCV, Tylki-Szyma\u0144ska A, Berry-Kravis E, Ezg\u00fc F, Ganju J, et al. Study design challenges and strategies in clinical trials for rare diseases: lessons learned from pantothenate kinase-associated neurodegeneration. Front Neurol. 2023;14:1098454. https:\/\/doi.org\/10.3389\/fneur.2023.1098454.","journal-title":"Front Neurol"},{"key":"3986_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0382-6","author":"D Pinto","year":"2016","unstructured":"Pinto D, Martin D, Chenhall R. The involvement of patient organisations in rare disease research: a mixed methods study in Australia. Orphanet J Rare Dis. 2016. https:\/\/doi.org\/10.1186\/s13023-016-0382-6.","journal-title":"Orphanet J Rare Dis"},{"key":"3986_CR34","unstructured":"Project dissemination webpage on AS.It.O.I website. https:\/\/www.asitoi.org\/as-it-o-i-al-fianco-del-irccs-istituto-ortopedico-rizzoli-a-supporto-per-due-progetti-di-studio\/ Accessed 31\/07\/\/2025."},{"key":"3986_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/hex.13625","author":"CQ Nguyen","year":"2022","unstructured":"Nguyen CQ, Kariyawasam D, Alba-Concepcion K, et al. Advocacy groups are the connectors\u2019: experiences and contributions of rare disease patient organization leaders in advanced neurotherapeutics. Health Expect. 2022. https:\/\/doi.org\/10.1111\/hex.13625.","journal-title":"Health Expect"},{"key":"3986_CR36","doi-asserted-by":"publisher","unstructured":"Gaasterland CMW, van der Weide MCJ, du Prie-Olthof MJ, et al. The patient\u2019s view on rare disease trial design - a qualitative study. Orphanet J Rare Dis. 2019. https:\/\/doi.org\/10.1186\/s13023-019-1002-z.","DOI":"10.1186\/s13023-019-1002-z"},{"key":"3986_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0718-x","author":"T Morel","year":"2017","unstructured":"Morel T, Cano SJ. Measuring what matters to rare disease patients - reflections on the work by the IRDiRC taskforce on patient-centered outcome measures. Orphanet J Rare Dis. 2017. https:\/\/doi.org\/10.1186\/s13023-017-0718-x.","journal-title":"Orphanet J Rare Dis"},{"key":"3986_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s40900-015-0004-9","author":"D Supple","year":"2015","unstructured":"Supple D, Roberts A, Hudson V, et al. From tokenism to meaningful engagement: best practices in patient involvement in an EU project [published correction appears in. Res Involv Engagem. 2015. https:\/\/doi.org\/10.1186\/s40900-015-0004-9.","journal-title":"Res Involv Engagem"},{"key":"3986_CR39","unstructured":"Gazzetta Ufficiale website. L. 11\/01\/2018: https:\/\/www.gazzettaufficiale.it\/eli\/id\/2018\/1\/31\/18G00019\/sg. Accessed 03\/06\/2024."},{"key":"3986_CR40","unstructured":"IMI \u2013 Innovative medicines initiative website. https:\/\/www.imi.europa.eu\/get-involved\/patients. Accessed on 03\/06\/2024."},{"key":"3986_CR41","unstructured":"Winder E. The Value\u2009+\u2009Project Toolkit. In: The Value\u2009+\u2009Project website.: https:\/\/www.eu-patient.eu\/globalassets\/projects\/valueplus\/value-toolkit.pdf. Accessed on 03\/06\/2024."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03986-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03986-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03986-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:50:24Z","timestamp":1759236624000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03986-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3986"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03986-9","relation":{"references":[{"id-type":"doi","id":"10.1001\/jamanetworkopen.2020.1965","asserted-by":"subject"}]},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"26 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by ethics committee and conducted according to the guidelines of the Declaration of Helsinki. The ethics committee of IRCCS Istituto Ortopedico Rizzoli approved the study with committee\u2019s reference number CE-AVEC 302\/2022\/Sper\/IOR. Informed consent has been collected from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"495"}}